---
search:
  boost: 3
---

# Opioids

This is a subcategory of Analgesic Agents.

**Ohio law requires prescribers to request and review an OARRS report before initially prescribing or personally furnishing any controlled substance, such as an opioid analgesic or a benzodiazepine, and gabapentin**

## Decision Trees

- [Analgesic Agents - Opioids - Butrans, Morphine Sulphate ER Tab, Nucynta](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNElUNVJKUFFOUTNSNkhXSUkxTjU3Nk1CRyQlQCN0PWcu){:target="_blank" rel="noopener"}

- [Analgesic Agents - Opioids - Non-Preferred Products - Long Acting](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBURVQwUlRYV1lXUlRPWUdRMEVPTzhTRzVQMyQlQCN0PWcu){:target="_blank" rel="noopener"}

- [Analgesic Agents - Opioids - Preferred Products - Short Acting](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUM0NJUkFUQUg4RlhMT1ZQWDJFVTExWEhNSSQlQCN0PWcu){:target="_blank" rel="noopener"}

- [Analgesic Agents - Opioids - 6a v6 Short Acting](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMUNXTjhTT0tSTDRZMkY2RkJER1NUTFdaNCQlQCN0PWcu){:target="_blank" rel="noopener"}

- [Analgesic Agents - Opioids - Transmucosal Fentanyl Products](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNk9QOFIxQ0szR0lPTjA1Tk1aRlBHTkE4QSQlQCN0PWcu){:target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                                               | Generic Name                                               |         Quantity          |        Time (Days)        |
|:--------------------------------------------------------|:-----------------------------------------------------------|:-------------------------:|:-------------------------:|
| Acetaminophen / Codeine <sup>QL</sup>                   | Acetaminophen w/ Codeine Tab 300-15 MG                     |            408            |            34             |
| Acetaminophen / Codeine <sup>QL</sup>                   | Acetaminophen w/ Codeine Tab 300-30 MG                     |            204            |            34             |
| Acetaminophen / Codeine <sup>QL</sup>                   | Acetaminophen w/ Codeine Tab 300-60 MG                     |            102            |            34             |
| Acetaminophen / Codeine <sup>QL</sup>                   | Acetaminophen w/ Codeine Soln 120-12 MG / 5 ML             |           2822            |            34             |
| Butalbital/Acetaminophen/Caffeine/Codeine <sup>QL</sup> | Butalbital-APAP-Caffeine w/ Codeine Cap 50-325-40-30 MG    |            238            |            34             |
| Butalbital/Aspirin/Caffeine/Codeine <sup>QL</sup>       | Butalbital-Aspirin-Caffeine w/ Codeine Cap 50-325-40-30 MG |            238            |            34             |
| Butorphanol <sup>QL</sup>                               | Butorphanol Soln 10 MG/ML                                  |            2.5            |            30             |
| Butrans <sup>BvG PA QL ==(Process by NDC)==</sup>       | Buprenorphine TD Patch Weekly (all strengths)              | Determined pursuant to PA | Determined pursuant to PA |
| Codeine <sup>QL</sup>                                   | Codeine Sulfate Tab 15 MG                                  |            408            |            34             |
| Codeine <sup>QL</sup>                                   | Codeine Sulfate Tab 30 MG                                  |            204            |            34             |
| Codeine <sup>QL</sup>                                   | Codeine Sulfate Tab 60 MG                                  |            102            |            34             |
| Hydrocodone/Acetaminophen <sup>QL</sup>                 | Hydrocodone/Acetaminophen Tab 5-325 MG                     |            204            |            34             |
| Hydrocodone/Acetaminophen <sup>QL</sup>                 | Hydrocodone/Acetaminophen Tab 7.5-325 MG                   |            136            |            34             |
| Hydrocodone/Acetaminophen <sup>QL</sup>                 | Hydrocodone/Acetaminophen Tab 10-325 MG                    |            102            |            34             |
| Hydrocodone/Acetaminophen <sup>QL</sup>                 | Hydrocodone/Acetaminophen Soln 7.5-325 MG / 15 ML          |           2040            |            34             |
| Hydrocodone/Acetaminophen <sup>QL</sup>                 | Hydrocodone/Acetaminophen Soln 7.5-500 MG / 15 ML          | Determined pursuant to PA | Determined pursuant to PA |
| Hydrocodone/Acetaminophen <sup>QL</sup>                 | Hydrocodone/Acetaminophen Soln 10-300 MG / 15 ML           | Determined pursuant to PA | Determined pursuant to PA |
| Hydrocodone/Acetaminophen <sup>QL</sup>                 | Hydrocodone/Acetaminophen Soln 10-325 MG / 15 ML           |           3060            |            34             |
| Hydromorphone IR <sup>QL</sup>                          |                                                            |                           |                           |
| Morphine IR <sup>QL</sup>                               | Morphine Sulfate IR Tab 15 MG                              |            68             |            34             |
| Morphine IR <sup>QL</sup>                               | Morphine Sulfate IR Tab 30 MG                              |            34             |            34             |
| Morphine Soln <sup>QL</sup>                             | Morphine Sulfate Oral Soln 10 MG / 5 ML                    |            510            |            34             |
| Morphine Soln <sup>QL</sup>                             | Morphine Sulfate Oral Soln 20 MG / 5 ML                    |            204            |            34             |
| Morphine Soln <sup>QL</sup>                             | Morphine Sulfate Oral Soln 100 MG / 5 ML (20 MG / ML)      |            68             |            34             |
| Morphine ER Tab <sup>PA QL</sup>                        | Morphine Sulfate ER Tab (all strengths)                    | Determined pursuant to PA | Determined pursuant to PA |
| Nucynta IR <sup>QL</sup>                                |                                                            |                           |                           |
| Nucynta ER <sup>PA QL</sup>                             |                                                            |                           |                           |
| Oxycodone <sup>QL</sup>                                 | Oxycodone HCI Cap 5 MG                                     |            136            |            34             |
| Oxycodone <sup>QL</sup>                                 | Oxycodone HCI Tab (all strengths excl 5 MG & 10 MG)        |            34             |            34             |
| Oxycodone <sup>QL</sup>                                 | Oxycodone HCI Tab 5 MG                                     |            136            |            34             |
| Oxycodone <sup>QL</sup>                                 | Oxycodone HCI Tab 10 MG                                    |            68             |            34             |
| Oxycodone <sup>QL</sup>                                 | Oxycodone HCI Tab Abuse Deterrent 5 MG                     |            272            |            34             |
| Oxycodone <sup>QL</sup>                                 | Oxycodone HCI Tab Abuse Deterrent 7.5 MG                   |            170            |            34             |
| Oxycodone <sup>QL</sup>                                 | Oxycodone HCI Soln 5 MG / 5 ML                             |            680            |            34             |
| Oxycodone/Acetaminophen <sup>QL</sup>                   | Oxycodone w/ Acetaminophen Tab 2.5-325 MG                  |            272            |            34             |
| Oxycodone/Acetaminophen <sup>QL</sup>                   | Oxycodone w/ Acetaminophen Tab 5-325 MG                    |            136            |            34             |
| Oxycodone/Acetaminophen <sup>QL</sup>                   | Oxycodone w/ Acetaminophen Tab 7.5-325 MG                  |            102            |            34             |
| Oxycodone/Acetaminophen <sup>QL</sup>                   | Oxycodone w/ Acetaminophen Tab 10-325 MG                   |            68             |            34             |
| Oxycodone/Acetaminophen <sup>QL</sup>                   | Oxycodone w/ Acetaminophen Soln 5-325 MG / 5 ML            |            680            |            34             |
| Tramadol <sup>QL</sup>                                  | Tramadol HCI Tab 50 MG                                     |            204            |            34             |
| Tramadol <sup>QL</sup>                                  | Tramadol HCI 100 MG                                        |            136            |            34             |
| Tramadol / Acetaminophen <sup>QL</sup>                  | Tramadol-Acetaminophen Tab 37.5-325 MG                     |            272            |            34             |

### Non-Preferred

| Non-Preferred                                                                                                | Generic Name                                                       |         Quantity          |        Time (Days)        |
|:-------------------------------------------------------------------------------------------------------------|:-------------------------------------------------------------------|:-------------------------:|:-------------------------:|
| Acetaminophen / Caffeine / Dihydrocodone <sup>QL</sup>                                                       | Acetaminophen / Caffeine / Dihydrocodone Cap / Tab (all strengths) | Determined pursuant to PA | Determined pursuant to PA |
| Belbuca <sup>QL</sup>                                                                                        | Buprenorphine Buccal Film (all strengths)                          | Determined pursuant to PA | Determined pursuant to PA |
| Benzhydrocodone / Acetaminophen <sup>QL</sup>                                                                | Benzhydrocodone / Acetaminophen (all strengths)                    | Determined pursuant to PA | Determined pursuant to PA |
| <span title = "Brand Preferred: Butrans">Buprenorphine TD Patch Weekly</span> <sup>QL, Brand Preferred</sup> | Buprenorphine TD Patch Weekly (all strengths)                      | Determined pursuant to PA | Determined pursuant to PA |
| Butalbital / Acetaminophen / Caffeine / Codeine 50 / 300 / 40 / 30mg <sup>QL</sup>                           | Butalbital-APAP-Caffeine w/ Codeine Cap 50-325-40-30 MG            |            238            |            34             |
| Dsuvia <sup>QL</sup>                                                                                         | Sufentanil Sublingual Tab (all strengths)                          | Determined pursuant to PA | Determined pursuant to PA |
| Fentanyl <sup>QL</sup>                                                                                       | Fentanyl TD Patch (all strengths)                                  | Determined pursuant to PA | Determined pursuant to PA |
| Hydrocodone Bitartrate ER 12HR Cap <sup>QL</sup>                                                             |                                                                    |                           |                           |
| Hydrocodone Bitartrate ER 24HR Tab <sup>QL</sup>                                                             |                                                                    |                           |                           |
| Hydrocodone / Acetaminophen <sup>QL</sup>                                                                    | Hydrocodone/Acetaminophen 5-300 MG                                 | Determined pursuant to PA | Determined pursuant to PA |
| Hydrocodone / Acetaminophen <sup>QL</sup>                                                                    | Hydrocodone/Acetaminophen 7.5-300 MG                               | Determined pursuant to PA | Determined pursuant to PA |
| Hydrocodone / Acetaminophen <sup>QL</sup>                                                                    | Hydrocodone/Acetaminophen 10-300 MG                                | Determined pursuant to PA | Determined pursuant to PA |
| Hydrocodone / Ibuprofen <sup>QL</sup>                                                                        | Hydrocodone / Ibuprofen Tab (all strengths)                        | Determined pursuant to PA | Determined pursuant to PA |
| Hydromorphone ER <sup>QL</sup>                                                                               |                                                                    |                           |                           |
| Levorphanol <sup>QL</sup>                                                                                    | Levorphanol Tab (all strengths)                                    | Determined pursuant to PA | Determined pursuant to PA |
| Meperidine <sup>QL</sup>                                                                                     | Meperidine HCI (all strengths & formulations)                      | Determined pursuant to PA | Determined pursuant to PA |
| Methadone <sup>QL</sup>                                                                                      | Methadone Concentrate Soln / Tab                                   | Determined pursuant to PA | Determined pursuant to PA |
| Morphine ER 24HR Cap QL                                                                                      |                                                                    |                           |                           |
| Oxycodone ER <sup>QL</sup>                                                                                   |                                                                    |                           |                           |
| Oxycodone/Ibuprofen QL                                                                                       | Oxycodone / Ibuprofen (all strengths)                              | Determined pursuant to PA | Determined pursuant to PA |
| Oxymorphone IR, ER <sup>QL</sup>                                                                             | Oxymorphone HCI Tab IR / ER (all strengths)                        | Determined pursuant to PA | Determined pursuant to PA |
| Pentazocine / Naloxone <sup>QL</sup>                                                                         | Pentazocine / Naloxone Tab (all strengths)                         | Determined pursuant to PA | Determined pursuant to PA |
| Seglentis <sup>QL</sup>                                                                                      | Celecoxib / Tramadol (all strengths)                               | Determined pursuant to PA | Determined pursuant to PA |
| Tramadol ER, Sol <sup>QL</sup>                                                                               | Tramadol HCI ER / Soln (all strengths)                             | Determined pursuant to PA | Determined pursuant to PA |
| Xtampza ER <sup>QL</sup>                                                                                     | Oxycodone ER Cap (all strengths)                                   | Determined pursuant to PA | Determined pursuant to PA |

## Authorizations

**Length of Authorizations**: For the course of therapy, up to 180 days. Initial short-acting and long-acting requests may only be authorized for up to 90 days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Buprenorphine Topical (Butrans) <sup>BvG ==(Process by NDC)==</sup> 

Buprenorphine Topical (Butrans) Criteria

- For doses greater than 5 mcg/hour must provide documentation of an inadequate clinical response with at least one opioid formulation taken for at least 60 of the last 90 days

[**Butrans 5mcg Guidance](https://special-spoon-f542dccd.pages.github.io/Pharmacist%20Reference%20Guide/Medication%20Guidance/opioid/butrans/?h=butrans)

### Morphine Sulfate ER (Kadian, MS Contin) & Tapentadol ER (Nucynta)

Morphine Sulfate ER (Kadian, MS Contin) & Tapentadol ER (Nucynta) Criteria

- Unless receiving for cancer pain, palliative care, or endof-life/hospice care, must provide documentation of an inadequate clinical response with at least 60 ^^one^^ opioid formulation taken for at least 60 of the last 90 days
- Must also meet LONG-ACTING OPIOID CRITERIA

### Non-Preferred

Non-Preferred Criteria

-   Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    -   For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
-   Must have had an inadequate clinical response of at least ^^7 days^^ of at least ^^two unrelated^^ preferred drugs of the same duration of action (SHORT-ACTING or LONG-ACTING)
    -   For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)
- Must also meet applicable SHORT-ACTING or LONG-ACTING OPIOID CRITERIA

[**Non-Preferred Opioid vs Cancer/Palliative care/Amputation Procedure](https://special-spoon-f542dccd.pages.github.io/Pharmacist%20Reference%20Guide/Medication%20Guidance/opioid/nonpreferredopioids/)

### Short-Acting

Additional SHORT-ACTING Opioids Criteria

-   The system defines an “initial request” as having no opioid claims in the previous 90 days
-   **Initial short-acting requests** can be authorized up to 90 days**
    -   Length of authorization is dependent on indication, previous patient utilization, and requested length of therapy (could be more restrictive)
    -   To exceed acute opioid limits, documentation of the following must be provided:
        -   Diagnosis code which must be for somatic type pain
        -   Prescriber attestation that the benefits and risks of opioid therapy has been discussed with patient
    -   Exemptions to the additional criteria:
        -   Patients receiving short-acting opioids for active cancer treatment, palliative care, and end-of-life/hospice care, sickle cell, severe burn, traumatic crushing of tissue, amputation, major orthopedic surgery
        -   Prescriber attestation that patient is not opioid naïve (i.e., new to Medicaid or was on higher dose in hospital)
     
[**Opioids- Short Acting Edit Overrides to be included with Approvals](https://special-spoon-f542dccd.pages.github.io/Pharmacist%20Reference%20Guide/Clinical%20and%20PA%20Notes/Control%20Substances/Opioids-Short%20Acting/)
        
- **Subsequent short-acting requests** can be authorized up to 180 days
    - Documentation of the following must be provided:
        - Current treatment plan
        - Demonstrated adherence to treatment plan through progress notes, including pain and function scores, random urine screenings results reviewed, concerns addressed, and no serious adverse outcomes observed
- **Dose escalation requests** can be authorized up to 180 days
    - Documentation of the following must be provided:
        - Prescriber attestation that dose escalation is likely to result in improved function or pain control
        - Requests for a cumulative daily dose >80 MED must be prescribed by or in consultation with a pain specialist, specialist in the area of the body affected by pain, or anesthesiologist

Patients with initial prescriptions for opioid therapy, defined as no rx claims for opioids in the last 90 days, will be limited to 30 MED per day and a maximum of 7 days per prescription. Prior authorization will be required to exceed these limits.

### Long-Acting

Additional LONG-ACTING Opioids Criteria

- The system defines an "inital long-acting request" as having no opioid claims in the previous 90 days
-   **Initial long-acting requests** can be authorized up to 90 days
    -   Documentation of the following must be provided:
        -   Request is a daily dose equivalent of ≤ 80 MED
        -   Inadequate clinical response to both non-opioid pharmacologic and non-pharmacologic treatments
        -   Current use of opioids for ≥ 60 of the last 90 days
        -   Treatment plan including risk assessment, substance abuse history, concurrent therapies, and requirements for random urine screenings (baseline urine drug tests must be submitted)
        -   Pain and function scores at each visit
        -   Opioid contract required to be in place and submitted with PA form
    -   Exemptions to the additional criteria:
        -   Patients receiving long-acting opioids for cancer pain, palliative care, or end-of-life/hospice care
-   **Subsequent long-acting requests** can be authorized up to 180 days
    -   Documentation of the following must be provided:
        -   Current treatment plan
        -   Demonstrated adherence to treatment plan through progress notes, including pain and function scores, random urine screenings results reviewed, concerns addressed, and no serious adverse outcomes observed
-   **Dose escalation requests** can be authorized up to 180 days
    -   Documentation of the following must be provided:
        -   Prescriber attestation that dose escalation is likely to result in improved function or pain control
        -   Requests for a cumulative daily dose >80 MED must be prescribed by pain specialist, specialist in the area of the body affected by pain, or anesthesiologist

### Transmucosal Fentanyl 

Additional Transmucosal Fentanyl Criteria

-   Must be prescribed by an oncologist, pain specialist, or hospice/palliative prescriber
-   Must be concurrently taking a long-acting opioid at a therapeutic dose of any of the following for at least ^^7 days^^ without adequate pain relief:

|                                  |                                      |
|----------------------------------|--------------------------------------|
| ≥ 60 mg oral morphine/day        | ≥ 8 mg oral hydromorphone/day        |
| ≥ 25 mcg/hr transdermal fentanyl | ≥ 25 mg oral oxymorphone/day         |
| ≥ 30 mg oral oxycodone/day       | Equianalgesic dose of another opioid |

### Buprenorphine Buccal Film

Buprenorphine Buccal Film (Beluca) Criteria:

- Must meet ADDITIONAL LONG-ACTING OPIOID CRITERIA

**QL** - Transmucosal Fentanyl: 4 doses per day

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7B73347C85-1D40-4514-80E9-9628185B51B4%7D&file=Denial%20Language%20Updated%2001012024.docx&action=embedview&mobiledirect=true&wdStartOn=4){:target="_blank" rel="noopener"}

[Criteria](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20criteria%20effective%2001.01.2024.pdf#page=10){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20effective%2001.01.2024.pdf#page=9){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/Quantity%20Limits.pdf){ :target="_blank" rel="noopener"}
